BrioHealth Solutions is developing the BrioVAD® System, an investigational Left Ventricular Assist System (LVAS) for advanced heart failure patients. This LVAS aims to improve pump performance and minimize complications like blood damage and clotting, while enhancing patient comfort with a smaller pump and fewer external connections.
Funding
Funding not disclosed
Founders
Product
Problem
Advanced heart failure presents a significant clinical challenge, with limited treatment options and a high mortality rate. Current mechanical circulatory support devices often have limitations that impact patient quality of life and can lead to complications.
Solution
BrioHealth Solutions is developing the BrioVAD® System, an investigational Left Ventricular Assist System (LVAS) designed to address the unmet needs of patients with advanced heart failure. The BrioVAD System utilizes advanced technology to improve pump performance and minimize complications such as blood damage and clotting. Its design prioritizes patient comfort and reduced infection risk through a smaller pump, lighter wearable components, and fewer connections. The system is currently being evaluated in the pivotal INNOVATE Trial across leading U.S. medical centers to assess its safety, efficacy, and impact on patient quality of life and hospitalizations.
Target Audience
The primary target audience includes cardiologists, cardiac surgeons, heart failure specialists, and patients diagnosed with advanced heart failure who are candidates for mechanical circulatory support.
Features
- Investigational Left Ventricular Assist System (LVAS) designed for advanced heart failure patients.
- Advanced pump technology engineered to minimize blood damage and reduce the risk of thrombosis.
- Compact pump design for improved patient fit, particularly for smaller individuals.
- Lightweight, wearable controller and battery system with a reduced number of external connections.
- Driveline designed for enhanced patient comfort and potentially lower risk of exit site infection.
- Currently undergoing evaluation in the FDA-approved INNOVATE pivotal trial in the U.S.
- Over 300 patients have received the BrioVAD pump outside the U.S.